Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
Retatrutide Clinical Research Findings The clinical development program for retatrutide has produced compelling data across multiple research endpoints: Weight Loss Efficacy: Phase 2 trials showed dose-dependent weight reduction ranging from 8.7% at the lowest dose to 24.2% at the highest dose over 48 weeks Metabolic Improvements: Participants demonstrated improvements in glycemic control, lipid profiles, and blood pressure measurements Safety Profile: Gastrointestinal effects (nausea, vomiting, diarrhea) were the most common adverse events, occurring in 60-80% of participants but generally rated as mild to moderate in severity Sustained Effects: Weight loss continued throughout the trial period without evidence of plateau, suggesting ongoing metabolic benefits These findings have positioned retatrutide as a leading candidate for advanced metabolic research
Devel Ther
All IV treatments at TUBeauty are formulated by medical professionals and administered under clinical protocols to ensure safety, comfort, and optimal results
Lin et al
Moreover, the upregulation of the HIF-1 signaling pathway and the downregulation of the Hippo pathway observed in the current transcriptomic and RT-PCR analyses should be interpreted as preliminary and descriptive findings
US$ 21.28
US$ 23.25
US$ 23.29
US$ 20.49
US$ 29.54
US$ 27.49
US$ 25.36
